Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Documenti analoghi

• Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase II trial of the Eastern Cooperative Oncology Group
  di: Argiris, Athanassios, et al.
  Pubblicazione: (2009)
• A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
  di: Argiris, Athanassios, et al.
  Pubblicazione: (2011)
• Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
  di: Argiris, A., et al.
  Pubblicazione: (2014)
• Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group
  di: Gilbert, Jill, et al.
  Pubblicazione: (2012)
• Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern Cooperative Oncology Group E2303
  di: Psyrri, Amanda, et al.
  Pubblicazione: (2014)